Biblio

Author Title [ Type

] Year

Filters: Author is Mutsaers, Pim G N J [Clear All Filters]

Journal Article

Abramson JS, Johnston PB, Kamdar M, Ibrahimi S, Izutsu K, Arnason JE, Glass B, Mutsaers PGNJ, Lunning M, Braverman J, et al. Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCL. Blood Adv. 2022.

Brink M, Meeuwes FO, van der Poel MWM, Kersten MJosé, Wondergem M, Mutsaers PGNJ, Böhmer LH, Woei-A-Jin FJSherida, Visser O, Oostvogels R, et al. Impact of Etoposide and ASCT on Survival Among Patients <65 years With Stage II-IV PTCL; a Population-Based Cohort Study.. Blood. 2022.

Meeuwes FO, Brink M, van der Poel MWM, Kersten MJosé, Wondergem M, Mutsaers PGNJ, Böhmer L, Woei-A-Jin S, Visser O, Oostvogels R, et al. Impact of rituximab on treatment outcomes of patients with angioimmunoblastic T-cell lymphoma; a population-based analysis. Eur J Cancer. 2022;176:100-109.

Abramson JS, Solomon SR, Arnason JE, Johnston PB, Glass B, Bachanova V, Ibrahimi S, Mielke S, Mutsaers PGNJ, Hernandez-Ilizaliturri FJ, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood. 2022.